financetom
Business
financetom
/
Business
/
Archer Aviation raises $300 million in BlackRock-backed funding
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Archer Aviation raises $300 million in BlackRock-backed funding
Feb 11, 2025 5:59 AM

Feb 11 (Reuters) - Air-taxi maker Archer Aviation ( ACHR )

said on Tuesday it has raised $300 million in a funding

round that consisted of institutional investors including

accounts managed by BlackRock ( BLK ).

Archer expects the capital raise to help it accelerate the

development of its hybrid aircraft platform and further

reinforce its balance sheet.

"We are raising additional capital to help us invest in

critical capabilities like composites and batteries to help

enable us to capture this opportunity and more," CEO Adam

Goldstein said.

The additional capital brings Archer's total liquidity to

about $1 billion currently, the company said on Tuesday.

The company's statement did not disclose the valuation at

which the new capital was raised.

The latest fundraising comes amid a cash crunch in the

electric vertical takeoff and landing (eVTOL) industry, driven

by technological and regulatory challenges. However, analysts

believe Archer is well positioned to endure these difficulties

and achieve certification.

The company previously raised $430 million in December

through an equity offering that had defense technology company

Anduril and existing investors such as United Airlines

and Stellantis ( STLA ), as well as new backers such as

Wellington Management and Abu Dhabi investment holding company

2PointZero, participate in the fundraising.

Santa Clara, California-based Archer said in its preliminary

fourth-quarter results that its adjusted operating expenses were

in line with its forecast range of $95 million to $110 million.

It also said it does not expect its total adjusted operating

expenses for the first quarter of 2025 to materially increase

above its Q4 guided range.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug
Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug
May 15, 2024
04:26 AM EDT, 05/15/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said Tuesday that the latter has initiated a rolling submission of a biologics license application to the US Food and Drug Administration for lecanemab-irmb subcutaneous autoinjector as a weekly maintenance treatment for early Alzheimer's disease. The application came after the treatment, commercially known as Leqembi, was granted FDA fast-track...
New York Community Bancorp to Sell $5 Billion in Mortgage Warehouse Loans to JPMorgan Chase Bank
New York Community Bancorp to Sell $5 Billion in Mortgage Warehouse Loans to JPMorgan Chase Bank
May 15, 2024
04:12 AM EDT, 05/15/2024 (MT Newswires) -- New York Community Bancorp ( NYCB/PU ) said Tuesday it has entered into a commitment letter to sell about $5 billion in mortgage warehouse loans to JPMorgan Chase Bank. The sale is expected to close in Q3. Shares of New York Community Bancorp gained almost 6% in after-market hours on Tuesday. Price: 4.1200,...
Novonix Signs Testing, Development Deal With Volkswagen-Owned PowerCo
Novonix Signs Testing, Development Deal With Volkswagen-Owned PowerCo
May 15, 2024
04:32 AM EDT, 05/15/2024 (MT Newswires) -- Novonix ( NVX ) said late Tuesday it signed a non-exclusive testing and development agreement with Volkswagen-owned PowerCo to come up with synthetic graphite anode materials for electric vehicle batteries. The companies could later enter into a supply agreement for the products developed under the deal, Novonix ( NVX ) said. Financial terms...
Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
May 15, 2024
04:24 AM EDT, 05/15/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Arcutis Biotherapeutics' ( ARQT ) shares surged more than 20% in premarket activity on Wednesday after the company reported a narrower loss and handily beat market expectations for sales. The company reported a Q1 loss late Tuesday of $0.32 per diluted...
Copyright 2023-2026 - www.financetom.com All Rights Reserved